Blume-Peytavi U, Fowler J, Kemény L, et al. - Researchers conducted this multicentre, open-label, 52-week study to assess the long-term effectiveness and safety of trifarotene in both facial and truncal acne. Participants in the study were patients with moderate facial and truncal acne received trifarotene 50 μg/g cream (trifarotene). The study was completed by 342 out of 453 patients recruited. Data reported that trifarotene-related treatment-emergent adverse events (TEAEs) have been reported in 12.6% of patients and none have been serious. Most of the associated TEAEs were cutaneous and occurred over the first 3 months. In this 52-week study, once-daily use of 50 μg/g trifarotene cream in patients with moderate facial and truncal acne was safe, well tolerated and effective, providing patients with continuous improvement over time. The current findings also support trifarotene's acceptable safety profile.